"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Trial ID or NCT#

NCT00056407

Status

not recruiting iconNOT RECRUITING

Purpose

This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

Eligibility Criteria

Ages Eligible for Study: 50 Years to 75 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Harcharan Gill
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist, Urologic surgeon
Kathryn Simmons Stamey Professor, Emeritus

Contact us to find out if this trial is right for you.

Contact

Kristin Hirabayashi
6507361362

View on ClinicalTrials.gov